



The Complete Blood Count Modified Results in Patients with Complicated Colorectal Cancer

Georgiana Bianca Constantin^{1*}, D Firescu^{1,2}, D Voicu¹, Cristina Șerban^{1,2}, Laura Rebegea^{1,2}, Corina Pălivan Manole^{1,2}, R Mihailov^{1,2}, B Ștefănescu^{1,2}, Rodica Bîrlă³ and S Constantinoiu³

¹Faculty of Medicine and Pharmacy, Dunarea de Jos University, Galati, Romania

²Clinical Emergency County Hospital "St. Ap. Andrei", Galati, Romania

³Carol Davila University of Medicine and Pharmacy, Bucharest, Romania



Abstract

Introduction: Among the factors on which the long-term survival of patients with colorectal cancer depends, the biological status at admission is essential and it is well reflected by a simple, routine analysis: The complete blood count (CBC). The link between the values of the hemoleukogram parameters and the diagnosis of colorectal cancers, but also between the changes in the hemoleukogram and the prognosis of patients with colorectal cancer is well documented in the literature. The aim of this study is to show the link between CBC changes at admission and the survival of patients with complicated colorectal cancer.

Patients and methods: We conducted a retrospective study that included 431 patients admitted and operated in emergency for complicated colorectal cancer, in the Surgery II Clinic of the Clinical Emergency County Hospital "St. Ap. Andrei" from Galati between 2008-2017. We made statistical correlations between the 4 types of emergency operations (external derivations, Hartmann, internal derivations and resections with anastomosis) and CBC changes, as well as a survival analysis depending on the presence of these changes.

Results: The presence of anemia at admission is statistically significant correlated with the practice of emergency colostomies and the presence of leukocytosis is correlated with Hartmann operations. In our study, only the anemia was a negative prognostic factor for the long-term survival of patients with complicated colorectal cancer.

Conclusions: The complete blood count is a routine, simple, cost-effective laboratory test that can be a very useful tool in assessing the prognosis of patients with complicated colorectal cancer.

Keywords

Complete blood count, Complicated colorectal cancer

Introduction

According to the data provided by the GLOBOCAN 2018 statistics, which sums up data from 185 countries, the colorectal cancer ranks 3rd in incidence globally (after lung and breast cancer) and 2nd in mortality by cancer (after lung cancer) [1]. Despite the improvements in diagnostic tools and screening options, a worrying percentage of patients still present in emergency with complicated tumors.

Although many therapeutic strategies have been developed in recent decades the long-term survival of patients with colorectal cancer, especially those presenting in emergency with complicated tumors, remains unsatisfactory [2].

The factors on which the long-term survival of patients with colorectal cancer, operated in emergency, depend on: Age, biological status at admission, symptoms, tumor location, invasion of neighboring organs, presence of secondary

disseminations, type of surgery, need for reinterventions, postoperative complications, histological type, tumor grading and staging [3,4]. Of all these factors, the biological status at admission is essential and it is well reflected by a simple, routine analysis: The complete blood count.

Several studies have shown the link between the values of

***Corresponding author:** Georgiana Bianca Constantin, Faculty of Medicine and Pharmacy, Dunarea de Jos University, Galati, Romania, Tel: 0749058284

Accepted: November 10, 2020

Published online: November 12, 2020

Citation: Constantin GB, Firescu D, Voicu C, et al. (2020) The Complete Blood Count Modified Results in Patients with Complicated Colorectal Cancer. Sch J Emerg Med Crit Care 4(1):79-84

hemoleukogram parameters and the diagnosis of colorectal cancers [5-7], but also between hemoleukogram changes and the prognosis of patients with colorectal cancer [8].

The aim of this study is to show the link between CBC changes at admission and the survival of patients with complicated colorectal cancer.



Patients and Methods

We conducted a retrospective study that included 431 patients admitted and operated in emergency for complicated colorectal cancer, in the Surgery II Clinic of the Clinical Emergency County Hospital "St. Ap. Andrei" from Galati between 2008-2017.

The patient data were collected from observation sheets, surgical protocols and histopathological reports.

We analyzed the following paraclinical factors: Hemoglobin, hematocrit, leukocyte and platelet values at admission.

We made statistical correlations between the 4 types of emergency operations (external derivations, Hartmann, internal derivations and resections with anastomosis) and CBC changes, as well as a survival analysis depending on the presence of these changes.



Statistical analysis

The survival analysis was made from the time of diagnosis until the time of death of patients or until the end of follow-up in the study (01.10.2019).

As prognostic factors, survival curves were analyzed using the Kaplan-Meier method and the analysis of statistical significance was performed with the Log Rank (Mantel-Cox) and Breslow (Generalized Wilcoxon) tests.

The mean and median for the survival time were calculated for estimating survival at 6, 12, 18, 24, 48, and 60 months.

The statistical analysis was performed using SPSS software (version 23.0). Statistical conclusions were formulated using as a statistically significant difference threshold the value $p < 0.05$ for all calculations performed.

Results

Of the patients included in the study, 299 (69.37%) were anemic at admission. Of these, 107 required whole blood transfusions or erythrocyte mass (Figure 1). According to the reference interval of the laboratory of the Clinical Emergency County Hospital from Galati, we considered anemia hemoglobin values lower than 11 g/dl and hematocrit values lower than 35%.

63 patients (14.61%) had leukocytosis at admission (a number of leukocytes $> 10000/\mu\text{l}$) (Figure 2).

The statistical analysis regarding the correlation of the types of operations performed with the laboratory analyzes at admission revealed the following data: Statistically significant difference between patients with anemia who underwent colostomies, respectively Hartmann operations (p value = 0.002115- Pearson test Chi-Square); statistically significant difference between patients with anemia needing transfusions at whom we practiced colostomies, respectively internal derivations (p value = 0.018961- Pearson Chi-Square test) (Table 1).

We also found significant differences in the correlation of the type of emergency surgery with the presence of leukocytosis at admission. Thus, in patients with leukocytosis at admission, Hartmann-type interventions were preferred over colostomies (p value = 0.000342- Pearson Chi-Square test) (Table 1).

The survival analysis

The presence of anemia at admission (Table 2): Of the 260 patients with anemia at admission, 251 died and 9 (3.5%) survived until 01.10.2019. Of the 131 patients without anemia at admission, 128 died and 3 (2.3%) were alive by the end of the study.

Comparing the survival on the 2 groups, there is a statistically significant difference (test for the 2 curves: p value = 0.000006 Log Rank (Mantel-Cox)) (Table 3).

On the graph it can be seen that the 2 survival curves for patients with anemia at admission and those without anemia do not overlap (Figure 3).

Table 1: Correlation of the type of surgery with laboratory data at the admission- statistical data processing.

	Type op = 1 (N=179 - 41.5%)	Type op = 2 (N = 134 - 31.1%)	Type op = 3 (N = 29 - 6.7%)	Type op = 4 (N = 89 - 20.9%)	P value (test)
Anemia = yes	134/179 (74.9%)	76/134 (56.7%)	22/29 (75.9%)	67/89 (75.3%)	0.002115 (Pearson Chi-Square)
Anemia needing transfusions = yes	55/179 (30.7%)	27/134 (20.1%)	2/29 (6.9%)	23/89 (25.8%)	0.018961 (Pearson Chi-Square)
Leukocytosis = yes	13/179 (7.3%)	33/134 (24.6%)	4/29 (13.8%)	13/89 (14.6%)	0.000342 (Pearson Chi-Square)
Trombocytopenia = yes	4/179 (2.2%)	5/134 (3.7%)	0/29 (0.0%)	0/89 (0.0%)	0.092185 (Likelihood Ratio)

Table 2: The presence of anemia at admission.

Case processing summary				
Anemia	Total N	N of events (deaths)	Censored (survivors)	
			N	Percent
Yes	260	251	9	3.5%
No	131	128	3	2.3%
Overall	391	379	12	3.1%

Table 3: Comparing the survival on the 2 groups, there is a statistically significant difference (test for the 2 curves: p value = 0.000006 Log Rank (Mantel-Cox)).

Overall comparisons			
	Chi-Square	df	Sig. (p value)
Log rank (Mantel-Cox)	20.432	1	0.000006
Breslow (Generalized Wilcoxon)	20.740	1	0.000005




Table 4: Estimation of the mean and median survival based on the presence of anemia at admission.

Anemia	Mean				Median			
	Estimate	Std. error	95% Confidence interval		Estimate	Error	95% Confidence interval	
			Lower bound	Upper bound			Lower bound	Upper bound
Yes	17.124	0.819	15.518	18.730	12.000	0.465	11.089	12.911
No	25.151	1.455	22.300	28.002	18.000	3.179	11.769	24.231
Overall	19.815	0.754	18.338	21.293	14.000	0.616	12.792	15.208

Table 5: Correlation of anemia with the survival- Cox univariate survival regression.

	B	SE	Wald	df	Sig.	Exp (B)	95.0% CI for Exp (B)	
							Lower	Upper
Anemia	0.240	0.055	18.778	1	0.000015	1.272	1.141	1.418

Table 6: Survival depending on the presence of anemia at admission.

Survivors	6 months	12 months	18 months	24 months	36 months	60 months
Yes	88.8%	48.1%	28.5%	19.6%	10.9%	1.2%
No	93.1%	68.7%	49.6%	45.8%	26.4%	2.5%

Table 7: The presence of severe anemia with preoperative transfusion requirements.

Case processing summary				
Anemia-transfusion preop.	Total N	N of events (deaths)	Censored (survivors)	
			N	Percent
Yes	81	79	2	2.5%
No	310	300	10	3.2%
Overall	391	379	12	3.1%

Table 8: Comparing the survival on the 2 groups, no statistically significant difference is found (test for the 2 curves: p value = 0.921275 Log Rank (Mantel-Cox)).

Overall comparisons			
	Chi-Square	df	Sig. (p value)
Log rank (Mantel-Cox)	0.010	1	0.921275
Breslow (Generalized Wilcoxon)	0.140	1	0.708304

The mean estimated survival time to death for patients with anemia at admission is 17,124 and for patients without anemia is 25,151. The median survival time for patients with anemia is 12,000 and for patients without anemia is 18,000 (Table 4).

The risk of death for patients with anemia is: HR = 1,272, 95% CI = (1,141, 1.418) (p value = 0.000015) (Table 5). So the presence of anemia is a risk factor.

The percentages of patients surviving at various times (6 months, 12 months, etc.) are explicitly shown in Table 6. The 5-years survival of patients with anemia at admission is 1.2%, while in patients without anemia, the 5-years survival is 2.5%.

The presence of severe anemia with preoperative transfusion requirements (Table 7): Of the 81 patients with anemia needing transfusions, 79 died and 2 (2.5%) survived un-

til 01.10.2019. Of the 310 patients without anemia needing transfusions, 300 died and 10 (3.2%) were alive at the end of the study.

Comparing the survival on the 2 groups, no statistically significant difference is found (test for the 2 curves: p value = 0.921275 Log Rank (Mantel-Cox)) (Table 8).

The presence of leukocytosis at admission (Table 9): Of the 46 patients with leukocytosis at admission, 45 died by 01.10.2019, and 1 (2.2%) survived. Of the 345 patients without leukocytosis at admission, 334 died and 11 (3.2%) were alive at the end of the study.

Comparing the survival on the 2 groups, we find a difference close to the limit of statistical significance (test for the 2 curves: p-value = 0.099868 Log Rank (Mantel-Cox)) (Table 10).

Table 9: The presence of leukocytosis at admission.

Case processing summary				
Leukocytosis	Total N	N of events (deaths)	Censored (survivors)	
			N	Percent
Yes	46	45	1	2.2%
No	345	334	11	3.2%
Overall	391	379	12	3.1%

Table 10: Comparing the survival on the 2 groups, we find a difference close to the limit of statistical significance (test for the 2 curves: p value = 0.099868 Log Rank (Mantel-Cox)).

Overall comparisons			
	Chi-square	df	Sig. (p value)
Log rank (Mantel-Cox)	2.708	1	0.099868
Breslow (Generalized Wilcoxon)	1.673	1	0.195827

Table 11: The presence of thrombocytopenia at admission.

Case Processing Summary				
Thrombocytopenia	Total N	N of Events (deaths)	Censored (survivors)	
			N	Percent
Yes	6	6	0	0.0%
No	385	373	12	3.1%
Overall	391	379	12	3.1%

Table 12: Comparing the survival on the 2 groups, no statistically significant difference is found (test for the 2 curves: p value = 0.106936 Log Rank (Mantel-Cox)).

Overall Comparisons			
	Chi-Square	df	Sig. (p value)
Log rank (Mantel-Cox)	2.599	1	0.106936
Breslow (Generalized Wilcoxon)	1.162	1	0.280962

The presence of thrombocytopenia at admission (Table 11): Of the 6 patients with thrombocytopenia at admission, none survived until 01.10.2019. Of the 385 patients without thrombocytopenia, 373 died and 12 (3.1%) were alive at the end of the study.

Comparing the survival on the 2 groups, no statistically significant difference is found (test for the 2 curves: p value = 0.106936 Log Rank (Mantel-Cox)) (Table 12).

Discussions

There are numerous studies in the literature evaluating the link between changes in complete blood count results and the survival of colorectal cancer patients, but few include patients operated in emergency.

In this study, in which we included only patients with complicated colorectal tumors, we showed that anemia is a risk factor and for the other parameters no statistical significance was obtained.

We showed that the presence of anemia at admission correlates well with the practice of colostomes in emergency and the presence of leukocytosis correlates with Hartmann

operations. In our study, only the anemia was a negative prognostic factor for the long-term survival of patients with complicated colorectal cancer.

The anemia is very common in patients with colorectal cancer, as shown by most studies [9-13]. A recent study, published in Brazil, shows that the anemia is a risk factor for patients with colorectal cancer operated in emergency, as in our study, and anemia with transfusion requirements was an independent risk factor [14], a correlation which we did not find.

The leukocytosis, a faithful sign of the presence of inflammation and/or infection, has been associated with the practice of Hartmann surgery in other studies [15,16], as in our study.

Some recent studies indicate the leukocytosis as a prognostic factor for colorectal cancer patients [17], which we did not find in our study.

Some authors found a shorter survival in patients with complicated colorectal cancer with preoperative thrombocytosis [18], a correlation that we did not find in our study.

Conclusions

We obtained statistically significant results in correlating colostomies with the presence of anemia at admission and correlating Hartmann operations with the presence of leukocytosis at admission.

The anemia turned out to be a paraclinical prognostic factor for patients with complicated colorectal cancer. The complete blood count is a routine, simple, cost-effective laboratory test that can be a very useful tool in assessing the prognosis of patients with complicated colorectal cancer.

References

1. Bray F, Ferlay J, Soerjomataram I, et al. (2018) Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. *CA Cancer J Clin* 68: 394-424.
2. Wu Q, Hu T, Zheng E, et al. (2017) Prognostic role of the lymphocyte-to-monocyte ratio in colorectal cancer: An up-to-date meta-analysis. *Medicine (Baltimore)* 96: e7051.
3. F Zaharie, L Mocan, T Mocan, et al. (2011) Managementul chirurgical în urgență al ocuziilor prin cancer colonice și rectale. *Chirurgia* 106: 479-484.
4. Bărbulescu M (2007) Factorii prognostici ai cancerului colorectal (I). *Jurnalul de Chirurgie Iași* 3: 117-129.
5. Spell DW, Jones DV, Harper WF, et al. (2004) The value of a complete blood count in predicting cancer of the colon. *Cancer Detect Prev* 28: 37-42.
6. Hamilton W, Lancashire R, Sharp D, et al. (2008) The importance of anaemia in diagnosing colorectal cancer: A case-control study using electronic primary care records. *Br J Cancer* 98: 323-327.
7. Virdee PS, Kirtley S, Elhoussein L, et al. (2019) Components of the full blood count as risk factors for colorectal cancer detection: A systematic review protocol. *BMJ Open* 9: e032759.
8. Birks J, Bankhead C, Holt TA, et al. (2017) Evaluation of a prediction model for colorectal cancer: Retrospective analysis of 2.5 million patient records. *Cancer Med* 6: 2453-2460.
9. Väyrynen JP, Tuomisto A, Väyrynen SA, et al. (2018) Preoperative anemia in colorectal cancer: Relationships with tumor characteristics, systemic inflammation, and survival. *Sci Rep* 8: 1126.
10. Siegel R, Ma J, Zou Z, et al. (2014) Cancer statistics, 2014. *CA Cancer J Clin* 64: 9-29.
11. Sadahiro S, T Suzuki, N Tokunaga, et al. (1998) Anemia in patients with colorectal cancer. *J Gastroenterol* 33: 488-494.
12. James R Dunne, Christopher J Gannon, Tiffany M Osborn, et al. (2002) Preoperative anemia in colon cancer: Assessment of risk factors. *Am Surg* 68: 582-587.
13. Constantin GB, Berbec S, Voicu D, et al. (2020) The use of Metronidazole in Clostridium difficile infection at patients with complicated colorectal cancers operated in emergency. *Rev Chim* 71: 516-521.
14. Ramos RF, Santos Dos-Reis LC, Beatriz Esteves Borgeth Teixeira, et al. (2017) Cirurgia no cancer de colon empacientes operados de emergencia. *Rev Col Bras Cir* 44: 465-470.
15. Moghadamyeghaneh Z, Hanna M, Carmichael J, et al. (2015) Preoperative leukocytosis in colorectal cancer patients. *J Am Coll Surg* 221: 207-214.
16. Gastinger I, Marusch F, Koch A, et al. (2004) Hartmann's procedure indication in colorectal carcinoma. *Chirurg* 75: 1191-1196.
17. Diefenhardt M, Hofheinz RD, Martin D, et al. (2019) Leukocytosis and neutrophilia as independent prognostic immunological biomarkers for clinical outcome in the CAO/ARO/AIO-04 randomized phase 3 rectal cancer trial. *Int J Cancer* 145: 2282-2291.
18. Xu-Dong R, Zhang H, Wang XP, et al. (2018) Poor prognostic role of the pretreatment platelet counts in colorectal cancer. *Medicine(Baltimore)* 97: e10831.

DOI: 10.36959/592/387